Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Pharmacogenet Genomics. 2017 Aug;27(8):285–293. doi: 10.1097/FPC.0000000000000289

Figure 2.

Figure 2

Change in Lipoprotein (a) levels by HCAR2 (rs2454727) genotype in white subject from the AIM-HIGH trial. The reduction in Lp(a) in response to niacin was greater in homozygous 317M carriers compared with 317I carriers (p=0.0053 in the niacin group; p=0.37 in the placebo group; p-interaction =0.005). The boxes on the boxplots represent the 75th percentile, median, and 25th percentile.